Researchers demonstrated that prostatic hyperplasia is caused by using aromatase inhibitors to decrease oestrogen, leading to hyperphosphatemia and lowering dihydroxy vitamin D levels (Cheboub et al. The gene discussed is CYP19A1; the disease is benign prostatic hyperplasia.